Michael Borre

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3123050/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	21.4	652
2	Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. Cancer Cell, 2016, 30, 27-42.	16.8	486
3	A Dual Program for Translation Regulation in Cellular Proliferation and Differentiation. Cell, 2014, 158, 1281-1292.	28.9	414
4	Genomic Profiling of MicroRNAs in Bladder Cancer: miR-129 Is Associated with Poor Outcome and Promotes Cell Death <i>In vitro</i> . Cancer Research, 2009, 69, 4851-4860.	0.9	349
5	Coordinated epigenetic repression of the miRâ€200 family and miRâ€205 in invasive bladder cancer. International Journal of Cancer, 2011, 128, 1327-1334.	5.1	335
6	Enzalutamide in Men with Chemotherapy-naÃ ⁻ ve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. European Urology, 2017, 71, 151-154.	1.9	306
7	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nature Genetics, 2011, 43, 785-791.	21.4	265
8	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	21.4	264
9	Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncology, The, 2008, 9, 342-351.	10.7	257
10	Cellular Disposal of miR23b by RAB27-Dependent Exosome Release Is Linked to Acquisition of Metastatic Properties. Cancer Research, 2014, 74, 5758-5771.	0.9	237
11	Alternative Splicing in Colon, Bladder, and Prostate Cancer Identified by Exon Array Analysis. Molecular and Cellular Proteomics, 2008, 7, 1214-1224.	3.8	202
12	Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers. Clinical Cancer Research, 2011, 17, 5582-5592.	7.0	183
13	Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. European Urology, 2016, 70, 75-82.	1.9	174
14	Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2019, 37, 1051-1061.	1.6	174
15	Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet, The, 2021, 398, 131-142.	13.7	167
16	Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial. European Urology, 2009, 55, 1112-1123.	1.9	141
17	miR-145 induces caspase-dependent and -independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors. Oncogene, 2010, 29, 1073-1084.	5.9	135
18	Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. Journal of Clinical Oncology, 2018, 36, 2639-2646.	1.6	131

#	Article	IF	CITATIONS
19	Mutational Context and Diverse Clonal Development in Early and Late Bladder Cancer. Cell Reports, 2014, 7, 1649-1663.	6.4	128
20	Androgen-deprivation Therapy in Treatment of Prostate Cancer and Risk of Myocardial Infarction and Stroke: A Nationwide Danish Population-based Cohort Study. European Urology, 2014, 65, 704-709.	1.9	127
21	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Human Molecular Genetics, 2013, 22, 408-415.	2.9	118
22	DNA Methylation Signatures for Prediction of Biochemical Recurrence After Radical Prostatectomy of Clinically Localized Prostate Cancer. Journal of Clinical Oncology, 2013, 31, 3250-3258.	1.6	117
23	Efficacy of a multiprofessional rehabilitation programme in radical cystectomy pathways: A prospective randomized controlled trial. Scandinavian Journal of Urology, 2015, 49, 133-141.	1.0	116
24	Diagnosis of Bladder Cancer Recurrence Based on Urinary Levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 Hypermethylation. PLoS ONE, 2012, 7, e46297.	2.5	112
25	Diagnostic and Therapeutic Strategies for Prostate Cancer. Seminars in Nuclear Medicine, 2016, 46, 484-490.	4.6	112
26	Expression profiling of prostate cancer tissue delineates genes associated with recurrence after prostatectomy. Scientific Reports, 2015, 5, 16018.	3.3	108
27	Tumorâ€promoting macrophages induce the expression of the macrophageâ€specific receptor CD163 in malignant cells. International Journal of Cancer, 2012, 131, 2320-2331.	5.1	103
28	Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castrationâ€resistant prostate cancer and bone metastases who were painâ€free or mildly symptomatic for pain: a doubleâ€blind, placeboâ€controlled, randomized Phase II trial. BJU International, 2010, 106, 966-973.	2.5	94
29	Expression of TIP60 (tatâ€interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatmentâ€specific outcome of localised invasive bladder cancer. BJU International, 2012, 110, E1228-36.	2.5	92
30	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	12.8	88
31	Paired Exome Analysis Reveals Clonal Evolution and Potential Therapeutic Targets in Urothelial Carcinoma. Cancer Research, 2016, 76, 5894-5906.	0.9	87
32	Cathepsin E, Maspin, Plk1, and Survivin Are Promising Prognostic Protein Markers for Progression in Non-Muscle Invasive Bladder Cancer. American Journal of Pathology, 2012, 180, 1824-1834.	3.8	86
33	miRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer. BMC Medical Genomics, 2012, 5, 40.	1.5	86
34	Hypermethylation of the <i>GABREâ^¼miR-452â^¼miR-224</i> Promoter in Prostate Cancer Predicts Biochemical Recurrence after Radical Prostatectomy. Clinical Cancer Research, 2014, 20, 2169-2181.	7.0	86
35	Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine. European Urology Focus, 2018, 4, 825-833.	3.1	86
36	Profiling of circulating microRNAs for prostate cancer biomarker discovery. Drug Delivery and Translational Research, 2014, 4, 19-30.	5.8	84

#	Article	IF	CITATIONS
37	Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncology, The, 2014, 15, 592-600.	10.7	73
38	Exercise-based pre-habilitation is feasible and effective in radical cystectomy pathways—secondary results from a randomized controlled trial. Supportive Care in Cancer, 2016, 24, 3325-3331.	2.2	73
39	Multicenter Validation of Cyclin D1, MCM7, TRIM29, and UBE2C as Prognostic Protein Markers in Non-Muscle–Invasive Bladder Cancer. American Journal of Pathology, 2013, 182, 339-349.	3.8	71
40	Benzoxazinoids: Cereal phytochemicals with putative therapeutic and healthâ€protecting properties. Molecular Nutrition and Food Research, 2015, 59, 1324-1338.	3.3	71
41	Plasma Levels of Trefoil Factors are Increased in Patients with Advanced Prostate Cancer. Clinical Cancer Research, 2006, 12, 807-812.	7.0	70
42	Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling. Oncotarget, 2016, 7, 30760-30771.	1.8	70
43	Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 3290-3297.	1.6	69
44	⁶⁸ Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer. Journal of Nuclear Medicine, 2021, 62, 214-220.	5.0	64
45	Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts. BMC Cancer, 2010, 10, 646.	2.6	60
46	Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Scandinavian Journal of Urology, 2014, 48, 268-275.	1.0	59
47	The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4â€year data from the Combination of Avodart and Tamsulosin (CombAT) study. BJU International, 2011, 107, 1426-1431.	2.5	57
48	Internetâ€delivered mindfulnessâ€based cognitive therapy for anxiety and depression in cancer survivors: A randomized controlled trial. Psycho-Oncology, 2020, 29, 68-75.	2.3	57
49	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1121-1129.	2.5	56
50	Urinary engrailedâ€2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer. BJU International, 2012, 110, E287-92.	2.5	55
51	Multidisciplinary rehabilitation can impact on health-related quality of life outcome in radical cystectomy: secondary reported outcome of a randomized controlled trial. Journal of Multidisciplinary Healthcare, 2014, 7, 301.	2.7	53
52	The natural history of prostate carcinoma based on a Danish population treated with no intent to cure. Cancer, 1997, 80, 917-928.	4.1	52
53	Genome-wide analysis of allelic imbalance in prostate cancer using the Affymetrix 50K SNP mapping array. British Journal of Cancer, 2007, 96, 499-506.	6.4	50
54	Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer. British Journal of Cancer, 2013, 108, 420-428.	6.4	50

#	Article	IF	CITATIONS
55	Biomarker potential of <i><scp>ST</scp>6<scp>GALNAC</scp>3</i> and <i><scp>ZNF</scp>660</i> promoter hypermethylation in prostate cancer tissue and liquid biopsies. Molecular Oncology, 2018, 12, 545-560.	4.6	49
56	Promoter hypomethylation and upregulation of trefoil factors in prostate cancer. International Journal of Cancer, 2010, 127, 1857-1865.	5.1	48
57	Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Modern Pathology, 2012, 25, 902-910.	5.5	48
58	Consistent genomic alterations in carcinoma <i>in situ</i> of the urinary bladder confirm the presence of two major pathways in bladder cancer development. International Journal of Cancer, 2009, 125, 2095-2103.	5.1	45
59	Statin use and risk of prostate cancer: A Danish population-based case-control study, 1997–2010. Cancer Epidemiology, 2014, 38, 42-47.	1.9	45
60	A short-term cost-effectiveness study comparing robot-assisted laparoscopic and open retropubic radical prostatectomy. Journal of Medical Economics, 2011, 14, 403-409.	2.1	44
61	External Validation of a Multiplex Urinary Protein Panel for the Detection of Bladder Cancer in a Multicenter Cohort. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1804-1812.	2.5	44
62	Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma. Molecular Oncology, 2016, 10, 1450-1460.	4.6	44
63	Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. European Urology, 2018, 73, 870-876.	1.9	44
64	TUMOR CELL PROLIFERATION AND SURVIVAL IN PATIENTS WITH PROSTATE CANCER FOLLOWED EXPECTANTLY. Journal of Urology, 1998, 159, 1609-1614.	0.4	43
65	Penile vibratory stimulation in the recovery of urinary continence and erectile function after nerveâ€sparing radical prostatectomy: a randomized, controlled trial. BJU International, 2014, 114, 111-117.	2.5	41
66	Snail1 is overâ€expressed in prostate cancer. Apmis, 2009, 117, 196-204.	2.0	40
67	p53 ACCUMULATION ASSOCIATED WITH bcl-2, THE PROLIFERATION MARKER MIB-1 AND SURVIVAL IN PATIENTS WITH PROSTATE CANCER SUBJECTED TO WATCHFUL WAITING. Journal of Urology, 2000, 164, 716-721.	0.4	39
68	<i>HNF1B</i> variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer. Oncotarget, 2016, 7, 74734-74746.	1.8	38
69	Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naÃ⁻ve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results. European Urology, 2015, 68, 787-794.	1.9	37
70	The Prognostic Impact of Comorbidities on Renal Cancer, 1995 to 2006: A Danish Population Based Study. Journal of Urology, 2009, 182, 35-40.	0.4	36
71	Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer. Clinical Epigenetics, 2018, 10, 105.	4.1	36
72	A fiveâ€microRNA model (<i>pCaP</i>) for predicting prostate cancer aggressiveness using cellâ€free urine. International Journal of Cancer, 2019, 145, 2558-2567.	5.1	36

#	Article	IF	CITATIONS
73	Immune cell analyses of the tumor microenvironment in prostate cancer highlight infiltrating regulatory <scp>T</scp> cells and macrophages as adverse prognostic factors. Journal of Pathology, 2021, 255, 155-165.	4.5	36
74	Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients. Scientific Reports, 2017, 7, 40636.	3.3	35
75	Immunohistochemical determination of tumor angiogenesis measured by the maximal microvessel density in human prostate cancer. Apmis, 1998, 106, 463-469.	2.0	34
76	Impact of Comorbidity on Survival of Danish Prostate Cancer Patients, 1995–2006: A Population-Based Cohort Study. Urology, 2008, 72, 1258-1262.	1.0	34
77	Football Compared with Usual Care in Men with Prostate Cancer (FC Prostate Community Trial): A Pragmatic Multicentre Randomized Controlled Trial. Sports Medicine, 2019, 49, 145-158.	6.5	33
78	Impact of Comorbidity on Survival of Invasive Bladder Cancer Patients, 1996-2007: A Danish Population-based Cohort Study. Urology, 2010, 75, 393-398.	1.0	31
79	Prevalence of the <i>HOXB13</i> G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness. BJU International, 2016, 118, 646-653.	2.5	31
80	High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression. BMC Cancer, 2009, 9, 385.	2.6	30
81	Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial. PLoS Medicine, 2019, 16, e1002936.	8.4	30
82	Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients. Annals of Oncology, 2018, 29, 2003-2009.	1.2	29
83	Homeâ€based â€~exergaming' was safe and significantly improved 6â€min walking distance in patients with prostate cancer: a singleâ€blinded randomised controlled trial. BJU International, 2019, 124, 600-608.	2.5	29
84	High miR-449b expression in prostate cancer is associated with biochemical recurrence after radical prostatectomy. BMC Cancer, 2014, 14, 859.	2.6	28
85	Aberrant DOCK2, GRASP, HIF3A and PKFP Hypermethylation has Potential as a Prognostic Biomarker for Prostate Cancer. International Journal of Molecular Sciences, 2019, 20, 1173.	4.1	28
86	Comparison of methods of microvascular staining and quantification in prostate carcinoma: Relevance to prognosis. Apmis, 2002, 110, 177-185.	2.0	27
87	Variation in general practice prostate-specific antigen testing and prostate cancer outcomes: An ecological study. International Journal of Cancer, 2015, 136, 435-442.	5.1	27
88	DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure. , 1998, 36, 244-249.		26
89	Genetic and Epigenetic <i>SLC18A2</i> Silencing in Prostate Cancer Is an Independent Adverse Predictor of Biochemical Recurrence after Radical Prostatectomy. Clinical Cancer Research, 2009, 15, 1400-1410.	7.0	26
90	High levels of 5-hydroxymethylcytosine (5hmC) is an adverse predictor of biochemical recurrence after prostatectomy in ERG-negative prostate cancer. Clinical Epigenetics, 2015, 7, 111.	4.1	26

#	Article	IF	CITATIONS
91	Prostate cancer, comorbidity, and the risk of venous thromboembolism: A cohort study of 44,035 Danish prostate cancer patients, 1995â€2011. Cancer, 2015, 121, 3692-3699.	4.1	25
92	High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer. BMC Cancer, 2014, 14, 638.	2.6	24
93	Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study. Cancer Causes and Control, 2016, 27, 1067-1079.	1.8	24
94	Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone NaÃ ⁻ ve Prostate Cancer: 3-Year Open Label Followup Results. Journal of Urology, 2018, 199, 459-464.	0.4	24
95	FRMD6 has tumor suppressor functions in prostate cancer. Oncogene, 2021, 40, 763-776.	5.9	24
96	The Dilemma of Prostate Cancer:A Growing Human and Economic Burden Irrespective of Treatment Strategies. Acta Oncológica, 1997, 36, 681-687.	1.8	23
97	Downregulation of zinc finger protein 132 in prostate cancer is associated with aberrant promoter hypermethylation and poor prognosis. International Journal of Cancer, 2012, 130, 885-895.	5.1	23
98	Quantitative Tumor Perfusion Imaging with ⁸² Rb PET/CT in Prostate Cancer: Analytic and Clinical Validation. Journal of Nuclear Medicine, 2019, 60, 1059-1065.	5.0	23
99	Secretagogin is a new neuroendocrine marker in the human prostate. Prostate, 2007, 67, 472-484.	2.3	22
100	Chromosomal deletion, promoter hypermethylation and downregulation of <i>FYN</i> in prostate cancer. International Journal of Cancer, 2008, 122, 509-519.	5.1	22
101	RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy. Oncotarget, 2017, 8, 5774-5788.	1.8	22
102	Profiling of Circulating microRNAs in Prostate Cancer Reveals Diagnostic Biomarker Potential. Diagnostics, 2020, 10, 188.	2.6	22
103	Causes of death in men with prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata). Cancer Epidemiology, 2019, 59, 249-257.	1.9	21
104	In vivo CRISPR inactivation of Fos promotes prostate cancer progression by altering the associated AP-1 subunit Jun. Oncogene, 2021, 40, 2437-2447.	5.9	21
105	Active Surveillance for Localized Prostate Cancer: Nationwide Observational Study. Journal of Urology, 2019, 201, 520-527.	0.4	21
106	Quality of urological cancer diagnoses in the Danish National Registry of Patients. European Journal of Cancer Prevention, 2012, 21, 545-551.	1.3	20
107	Completeness of prostate cancer staging in the Danish Cancer Registry, 2004–2009. Clinical Epidemiology, 2012, 4 Suppl 2, 17.	3.0	20
108	Largeâ€scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels. Molecular Oncology, 2016, 10, 825-837.	4.6	20

#	Article	IF	CITATIONS
109	Oncological outcomes and complication rates after laparoscopicâ€assisted cryoablation: a European Registry for Renal Cryoablation (Eu <scp>RECA</scp>) multiâ€institutional study. BJU International, 2017, 119, 390-395.	2.5	20
110	Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis. International Journal of Molecular Sciences, 2017, 18, 2017.	4.1	20
111	Epigenetic silencing of MEIS2 in prostate cancer recurrence. Clinical Epigenetics, 2019, 11, 147.	4.1	20
112	Independent Validation of a Diagnostic Noninvasive 3-MicroRNA Ratio Model (uCaP) for Prostate Cancer in Cell-Free Urine. Clinical Chemistry, 2019, 65, 540-548.	3.2	20
113	Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential. Cells, 2020, 9, 1362.	4.1	20
114	The transcriptional landscape and biomarker potential of circular RNAs in prostate cancer. Genome Medicine, 2022, 14, 8.	8.2	19
115	Survival after radical prostatectomy for clinically localised prostate cancer: a populationâ€based study. BJU International, 2014, 113, 541-547.	2.5	18
116	Long-term Somatic Disease Risk in Adult Danish Cancer Survivors. JAMA Oncology, 2019, 5, 537.	7.1	18
117	Salvage radiation therapy following radical prostatectomy. A national Danish study. Acta Oncológica, 2016, 55, 598-603.	1.8	17
118	High-Throughput and Automated Acoustic Trapping of Extracellular Vesicles to Identify microRNAs With Diagnostic Potential for Prostate Cancer. Frontiers in Oncology, 2021, 11, 631021.	2.8	17
119	Benzoxazinoids in Prostate Cancer Patients after a Rye-Intensive Diet: Methods and Initial Results. Journal of Agricultural and Food Chemistry, 2016, 64, 8235-8245.	5.2	16
120	Parkinson's disease and risk of prostate cancer: A Danish population-based case-control study, 1995–2010. Cancer Epidemiology, 2016, 45, 157-161.	1.9	16
121	Multi-parametric magnetic resonance imaging monitoring patients in active surveillance for prostate cancer: a prospective cohort study. Scandinavian Journal of Urology, 2018, 52, 8-13.	1.0	16
122	Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells. American Journal of Pathology, 2019, 189, 2377-2388.	3.8	16
123	Deep Learning Improves Speed and Accuracy of Prostate Gland Segmentations on Magnetic Resonance Imaging for Targeted Biopsy. Journal of Urology, 2021, 206, 604-612.	0.4	16
124	Reduction of quality of life in prostate cancer patients: experience among 6200 men in the Nordic countries. Scandinavian Journal of Urology, 2016, 50, 330-337.	1.0	15
125	A lifestyle intervention among elderly men on active surveillance for non-aggressive prostate cancer: a randomised feasibility study with whole-grain rye and exercise. Trials, 2017, 18, 20.	1.6	15
126	Postoperative C-reactive protein concentration and clinical outcome: comparison of open cystectomy to robot-assisted laparoscopic cystectomy with extracorporeal or intracorporeal urinary diversion in a prospective study. Scandinavian Journal of Urology, 2017, 51, 381-387.	1.0	15

#	Article	IF	CITATIONS
127	Scandinavian Prostate Cancer Patients' Sexual Problems and Satisfaction With Their Sex Life Following Anti-Cancer Treatment. Sexual Medicine, 2018, 6, 210-216.	1.6	15
128	Use of Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis. Annals of Internal Medicine, 2019, 170, 443.	3.9	15
129	Internet-delivered Mindfulness-Based Cognitive Therapy for anxiety and depression in cancer survivors: Predictors of treatment response. Internet Interventions, 2021, 23, 100365.	2.7	15
130	Urethral pressure profile 6 months after radical prostatectomy may be diagnostic of sphincteric incontinence: Preliminary data after 12 months' follow-up. Scandinavian Journal of Urology and Nephrology, 2009, 43, 114-118.	1.4	14
131	Co-expression of HER3 and MUC1 is associated with a favourable prognosis in patients with bladder cancer. BJU International, 2015, 115, 163-165.	2.5	14
132	Perioperative Systemic Inflammatory Response following Robot-Assisted Laparoscopic Cystectomy vs. Open Mini-Laparotomy Cystectomy: A Prospective Study. Urologia Internationalis, 2017, 99, 436-445.	1.3	14
133	Patient-reported outcome measures after treatment for prostate cancer: Results from the Danish Prostate Cancer Registry (DAPROCAdata). Cancer Epidemiology, 2020, 64, 101623.	1.9	14
134	Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling. Genome Medicine, 2022, 14, 9.	8.2	14
135	Survival of prostate cancer patients in central and northern Denmark, 1998–2009. Clinical Epidemiology, 2011, 3 Suppl 1, 41.	3.0	13
136	Quality of venous thromboembolism diagnoses among prostate cancer patients in the Danish National Registry of Patients. Clinical Epidemiology, 2014, 6, 351.	3.0	13
137	The influence of cardiovascular morbidity on the prognosis in prostate cancer. Experience from a 12-year nationwide Danish population-based cohort study. BMC Cancer, 2011, 11, 519.	2.6	12
138	Completeness of bladder cancer staging in the Danish Cancer Registry, 2004–2009. Clinical Epidemiology, 2012, 4 Suppl 2, 25.	3.0	12
139	A novel combined miRNA and methylation marker panel (miMe) for prediction of prostate cancer outcome after radical prostatectomy. International Journal of Cancer, 2019, 145, 3445-3452.	5.1	12
140	Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, e814-e821.	1.9	12
141	The power of empirical data; lessons from the clinical registry initiatives in Scandinavian cancer care. Acta Oncológica, 2020, 59, 1343-1356.	1.8	12
142	Screening by lower urinary tract symptoms vs asymptomatic prostateâ€specific antigen levels leading to radical prostatectomy in Danish men: tumour characteristics and treatment outcome. BJU International, 2009, 104, 205-208.	2.5	11
143	Comorbidity and survival of Danish prostate cancer patients from 2000–2011: a population-based cohort study. Clinical Epidemiology, 2013, 5, 47.	3.0	11
144	Computed Tomography Contrast Enhancement Following Renal Cryoablation—Does it Represent Treatment Failure?. Journal of Endourology, 2015, 29, 1353-1360.	2.1	11

#	Article	IF	CITATIONS
145	The Danish Prostate Cancer Database. Clinical Epidemiology, 2016, Volume 8, 649-653.	3.0	11
146	Prostate cancer: in-bore magnetic resonance guided biopsies at active surveillance inclusion improve selection of patients for active treatment. Acta Radiologica, 2018, 59, 619-626.	1.1	11
147	p53 ACCUMULATION ASSOCIATED WITH bcl-2, THE PROLIFERATION MARKER MIB-1 AND SURVIVAL IN PATIENTS WITH PROSTATE CANCER SUBJECTED TO WATCHFUL WAITING. Journal of Urology, 2000, 164, 716-721.	0.4	11
148	A randomized phase III trial between adjuvant docetaxel and surveillance after radical prostatectomy for high risk prostate cancer: Results of SPCG12 Journal of Clinical Oncology, 2016, 34, 5001-5001.	1.6	11
149	Efficacy of teleâ€nursing consultations in rehabilitation after radical prostatectomy: a randomised controlled trial study. International Journal of Urological Nursing, 2011, 5, 123-130.	0.2	10
150	Smarcc1 expression: A significant predictor of disease-specific survival in patients with clinically localized prostate cancer treated with no intention to cure. Scandinavian Journal of Urology and Nephrology, 2011, 45, 91-96.	1.4	10
151	Changes in preoperative characteristics in patients undergoing radical prostatectomy – a 16-year nationwide analysis. Acta Oncológica, 2014, 53, 361-367.	1.8	10
152	Survival and PSA-markers for mortality and metastasis in nonmetastatic prostate cancer treated with androgen deprivation therapy. Cancer Epidemiology, 2015, 39, 623-632.	1.9	10
153	The Impact of Husbands' Prostate Cancer Diagnosis and Participation in a Behavioral Lifestyle Intervention on Spouses' Lives and Relationships With Their Partners. Cancer Nursing, 2016, 39, E1-E9.	1.5	10
154	Does comorbidity interact with prostate cancer to increase mortality? A Danish cohort study of 45 326 prostate cancer patients diagnosed during 1995–2011. Acta Oncológica, 2016, 55, 611-618.	1.8	10
155	Arterial Clamping Increases Central Renal Cryoablation Efficacy: An Animal Study. Technology in Cancer Research and Treatment, 2017, 16, 414-420.	1.9	10
156	Exploring the transcriptome of hormone-naive multifocal prostate cancer and matched lymph node metastases. British Journal of Cancer, 2018, 119, 1527-1537.	6.4	10
157	Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer Journal of Clinical Oncology, 2018, 36, 5006-5006.	1.6	10
158	Validity of the recorded codes of gonadotropin-releasing hormone agonist treatment and orchiectomies in the Danish National Patient Registry. Clinical Epidemiology, 2012, 4, 145.	3.0	9
159	Long-term urodynamic findings following radical prostatectomy and salvage radiotherapy. Scandinavian Journal of Urology, 2018, 52, 20-26.	1.0	9
160	Bioactive small molecules in commercially available cereal food: Benzoxazinoids. Journal of Food Composition and Analysis, 2017, 64, 213-222.	3.9	9
161	A phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific antigen (PSA) progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) Journal of Clinical Oncology, 2017, 35, 5004-5004.	1.6	9
162	Preoperative Nutritional Status And the Impact on Radical Cystectomy Recovery: An International Comparative Study. Urologic Nursing, 2016, 36, 133.	0.1	9

#	Article	lF	CITATIONS
163	Body mass index and prognostic markers at radical prostatectomy. Scandinavian Journal of Urology and Nephrology, 2008, 42, 230-236.	1.4	8
164	Computed Tomography Perfusion, Magnetic Resonance Imaging, and Histopathological Findings After Laparoscopic Renal Cryoablation: An In Vivo Pig Model. Technology in Cancer Research and Treatment, 2017, 16, 406-413.	1.9	8
165	Late urinary morbidity and quality of life after radical prostatectomy and salvage radiotherapy for prostate cancer. Scandinavian Journal of Urology, 2017, 51, 457-463.	1.0	8
166	Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome. Scientific Reports, 2020, 10, 10704.	3.3	8
167	Erythrocyte Sedimentation Rate—A Predictor of Malignant Potential in Early Prostate Cancer. Acta Oncológica, 1997, 36, 689-694.	1.8	7
168	Association between <i>in vivo</i> iododeoxyuridine labeling, MIBâ€1 expression, malignancy grade and clinical stage in human prostate cancer. Apmis, 1998, 106, 389-395.	2.0	7
169	Patient comorbidity is associated with conservative treatment of localized prostate cancer. Scandinavian Journal of Urology, 2015, 49, 366-370.	1.0	7
170	Shared care in prostate cancer: a three-year follow-up. Scandinavian Journal of Urology, 2016, 50, 346-351.	1.0	7
171	Renal cryoablation: five- and 10-year survival outcomes in patients with biopsy-proven renal cell carcinoma. Scandinavian Journal of Urology, 2020, 54, 408-412.	1.0	7
172	Safety and Effects of Football in Skeletal Metastatic Prostate Cancer: a Subgroup Analysis of the FC Prostate Community Randomised Controlled Trial. Sports Medicine - Open, 2021, 7, 27.	3.1	7
173	Non-invasive quantification of tumor blood flow in prostate cancer using O-HO PET/CT. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 292-302.	1.0	7
174	Bioinformatic identification of FGF, p38-MAPK, and calcium signalling pathways associated with carcinoma in situin the urinary bladder. BMC Cancer, 2008, 8, 37.	2.6	6
175	Outpatient endoscopic treatment of ureteric stones: Five years' experience in a self-contained outpatient surgery unit. Scandinavian Journal of Urology, 2015, 49, 395-399.	1.0	6
176	Preoperative Aspects and Dimensions Used for Anatomical Score Predicts Treatment Failures in Laparoscopic Cryoablation of Small Renal Masses. Journal of Endourology, 2016, 30, 537-543.	2.1	6
177	Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na+/K+-ATPase-density. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 532-542.	6.4	6
178	The HER4 isoform JM-a/CYT2 relates to improved survival in bladder cancer patients but only if the estrogen receptor \hat{I}_{\pm} is not expressed. Scandinavian Journal of Clinical and Laboratory Investigation, 2013, 73, 503-513.	1.2	5
179	Reply to C. Mary Schooling, Grace Sembajwe and Ilir Agalliu's Letter to the Editor re: Christina G. Jespersen, Mette NÃ,rgaard, Michael Borre. Androgen-deprivation Therapy in Treatment of Prostate Cancer and Risk of Myocardial Infarction and Stroke: A Nationwide Danish Population-based Cohort Study, Eur Urol. In press. http://dx.doj.org/10.1016/j.eururo.2013.02.002. European Urology, 2013.64_e61	1.9	5
180	Oncological outcome after primary prostate cryoablation compared with radical prostatectomy: A single-centre experience. Scandinavian Journal of Urology, 2014, 48, 27-33.	1.0	5

#	Article	IF	CITATIONS
181	Soluble HER3 predicts survival in bladder cancer patients. Oncology Letters, 2017, 15, 1783-1788.	1.8	5
182	Perceptions about screening for prostate cancer using genetic lifetime risk assessment: a qualitative study. BMC Family Practice, 2018, 19, 32.	2.9	5
183	Repeatability of tumor blood flow quantification with 82Rubidium PET/CT in prostate cancer—Âa test-retest study. EJNMMI Research, 2019, 9, 58.	2.5	5
184	Renal cryoablation – does deep endophytic ablation affect the renal collecting system?. Scandinavian Journal of Urology, 2020, 54, 33-39.	1.0	5
185	Positive Predictive Value of Benign Prostatic Hyperplasia and Acute Urinary Retention in the Danish National Patient Registry: A Validation Study. Clinical Epidemiology, 2020, Volume 12, 1281-1285.	3.0	5
186	Potential synergy between PSMA uptake and tumour blood flow for prediction of human prostate cancer aggressiveness. EJNMMI Research, 2021, 11, 12.	2.5	5
187	Evaluation of Predictors of Biochemical Recurrence in Prostate Cancer Patients, as Detected by 68Ga-PSMA PET/CT. Diagnostics, 2022, 12, 195.	2.6	5
188	Randomised double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy: study protocol. BMJ Open, 2022, 12, e050264.	1.9	5
189	5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors. International Journal of Molecular Sciences, 2019, 20, 1025.	4.1	4
190	The natural history of prostate carcinoma based on a Danish population treated with no intent to cure. Cancer, 1997, 80, 917-928.	4.1	4
191	Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients Journal of Clinical Oncology, 2014, 32, 62-62.	1.6	4
192	The relationship between tumor aggressiveness and cholinergic PET imaging in prostate cancer tissue. A proof-of-concept study. American Journal of Nuclear Medicine and Molecular Imaging, 2019, 9, 185-192.	1.0	4
193	Shared care is a model for patients with stable prostate cancer. Danish Medical Journal, 2013, 60, A4691.	0.5	4
194	lmproved survival of patients with prostate cancer in northern Denmark, 1985–2004. Scandinavian Journal of Urology and Nephrology, 2007, 41, 308-313.	1.4	3
195	Percentage of tumour-positive biopsy cores: An independent predictor of extraprostatic disease. Scandinavian Journal of Urology and Nephrology, 2009, 43, 109-113.	1.4	3
196	Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study. Cancer Causes and Control, 2020, 31, 139-151.	1.8	3
197	An inverse association between plasma benzoxazinoid metabolites and PSA after rye intake in men with prostate cancer revealed with a new method. Scientific Reports, 2022, 12, 5260.	3.3	3
198	Prostate cancer: To scan or not to scan for lymph node involvement?. Scandinavian Journal of Urology and Nephrology, 2007, 41, 501-506.	1.4	2

#	Article	IF	CITATIONS
199	Length of life gained with surgical treatment of prostate cancer: A population-based analysis. Scandinavian Journal of Urology, 2015, 49, 275-281.	1.0	2
200	Molecular imaging of cholinergic processes in prostate cancer using 11C-donepezil and 18F-FEOBV. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 906-910.	6.4	2
201	Renal Potassium Excretion Visualized on 82Rubidium PET/CT. Nuclear Medicine and Molecular Imaging, 2020, 54, 120-122.	1.0	2
202	Acute urinary retention and risk of cancer: population based Danish cohort study. BMJ, The, 2021, 375, n2305.	6.0	2
203	Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence. British Journal of Cancer, 2022, 126, 1004-1009.	6.4	2
204	Phased array magnetic resonance imaging for staging clinically localised prostrate cancer. Acta Oncológica, 2005, 44, 589-92.	1.8	2
205	Evaluation of robot-assisted laparoscopic versus open cystectomy and effect of carbon dioxide-pneumoperitoneum on histopathological findings in ureteroenteric anastomoses: results from an experimental randomized porcine study. Scandinavian Journal of Urology, 2017, 51, 50-56.	1.0	1
206	Robot-assisted laparoscopic cystectomy with intracorporeal urinary diversion vs. open mini-laparotomy cystectomy: evaluation of surgical inflammatory response and immunosuppressive ability of CO ₂ -pneumoperitoneum in an experimental porcine study. Scandinavian Journal of Urology, 2018, 52, 249-255.	1.0	1
207	Prostate Cancer Screening—The Need for and Clinical Relevance of Decision Analytical Models. JAMA Network Open, 2021, 4, e212182.	5.9	1
208	Clinico-Pathological Characterization of Hereditary, Familial and Sporadic Prostate Cancer. Open Journal of Urology, 2012, 02, 38-44.	0.1	1
209	Danish multidisciplinary cancer groups – DMCG.dk benchmarking consortium: Article series on cancer survival and mortality in Denmark 1995–2012. Acta Oncológica, 2016, 55, 1-1.	1.8	0
210	Reply to M. Nayan et al. Journal of Clinical Oncology, 2018, 36, 629-630.	1.6	0
211	Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study. BJU International, 2021, 128, 702-712.	2.5	0
212	Enzalutamide monotherapy: One-year extended follow-up of a phase 2 study in hormone-naive prostate cancer patients Journal of Clinical Oncology, 2014, 32, 5068-5068.	1.6	0
213	Regional differences in cardiovascular status and events in prostate cancer patients treated with a gonadotrophin-releasing hormone agonist vs antagonist: Results of a pooled analysis Journal of Clinical Oncology, 2015, 33, e16096-e16096.	1.6	0
214	Long-term efficacy and safety of enzalutamide (ENZ) monotherapy in hormone-naÃ ⁻ ve prostate cancer (HNPC): 3-year, open-label, follow-up results Journal of Clinical Oncology, 2017, 35, 220-220.	1.6	0
215	Adverse effect of docetaxel versus surveillance after radical prostatectomy for high risk prostate cancer: Post-hoc analysis of the prospective randomized, open-label phase III SPCG 12 trial Journal of Clinical Oncology, 2018, 36, 30-30.	1.6	0